AMNOG Reform - will Germany remain the most attractive market for orphan drugs?

Given the current reforms and adaptions in the German system, one can wonder if the German market might remain the most attractive to launch pharmaceutical products and especially orphan drugs. Are there still ways to get innovative products into the market and get paid well? What do we need to know in order to still gain from the strengths of the German market size and economic power? This might be an even more important question in a global climate of declining prices. This podcast was recorded as part of the „Let‘s talk rare“ podcast. In this discussion Dr. Stefan Walzer discusses with Owen Bryant, Georgie Rack and Fisentzos Stylianou, all working at Partners 4 Access, the specifics of orphan drugs in the AMNOG context. (https://partners4access.com/in....sights/podcasts/)Tak the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8BMAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de #podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #germany